Fed. Circ. Grapples With Double-Patenting In Enbrel Case
Sandoz urged a seemingly uncertain Federal Circuit panel Wednesday to undo a decision that will block its biosimilar of Amgen's multibillion-dollar drug Enbrel until 2029, saying the district court should've found...To view the full article, register now.
Already a subscriber? Click here to view full article